Mobile Version

OfficialLotto

Mayside Research

Tuesday, February 9, 2010

"He that is good for making excuses is seldom good for anything else."— Benjamin Franklin, (1706 - 1790)
SUBMIT PRESS RELEASE
Kvetcher In The Rye
BREAKING NEWS OP-ED BUSINESS SPORT LIFE LEISURE KNOWLEDGE POLITICS GOV44.COM OBITUARIES PRESS RELEASES  
JOURNALIST REGISTRATION LOGIN SIGN UP

Bioheart, Inc. - Medical Equipment - Deals And Alliances Profile - New Report Published

Newly released report, Bioheart, Inc. - Medical Equipment - Deals and Alliances Profile, provides detailed company analysis

Published on November 25, 2009

by Press Office

(Companiesandmarkets.com and OfficialWire)

LONDON, ENGLAND

Re-Tweet this article
 

Bioheart, Inc. is a biotechnology company focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic acute heart damage and peripheral vascular disease. MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient's heart with living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's clinical trials of MyoCell include the SEISMIC Trial, a completed 40 patient Phase II clinical trial conducted in Europe, and the MYOHEART Trial, a completed 20 patient, Phase I dose escalation trial conducted in the United States. In its pipeline, the Company has multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth proteins.

Bioheart, Inc. - Medical Equipment - Deals and Alliances Profile

Summary

Bioheart, Inc. (Bioheart) is a biotechnology company, engaged in the development and marketing of autologous cell therapies for the cardiovascular markets. It develops autologous cell therapies which is used for the treatment of chronic and acute heart damage. The company's product portfolio includes myocell, myocath, wound dressing kit, acute cell therapy and biopace. It is headquartered in Florida, United States

The Bioheart, Inc. - Medical Equipment - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company's major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers' businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors' business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.

Bioheart, Inc. - Medical Equipment - Deals and Alliances Profile: http://www.companiesandmarkets.com/r.ashx?id=XEMNX9D5F166517

Contact
CompaniesandMarkets.com
Mike King
info@companiesandmarkets.com
Tel: +44 203 086 8600




Posted   11/25/2009 7:24 AM


Updated   11/24/2009 5:41 PM    
 



Print ArticlePrint EmailEmail Post to DiggPost to Digg
Print ArticleRE-PRINT PERMISSION RSS Local RSS Feed

All form fields are required.

OfficialWire is not storing your Twitter login data!

What would you do with €100 million?
Your UK Registered Office!

You are here:HomePRESS RELEASES Britain Publishing